Therapeutic Potential for New ALS Drug According to a recent study published in JAMA Neurology, ezogabine, an experimental drug, is found to have potential therapeutic possibilities for ALS treatment. “Most importantly, ezogabine decreased cortical and spinal motor neuron excitability in …
January 2021 Foundation eNews
ALS Disability Insurance Access Act Signed into Law We are excited to announce that on December 22, the ALS Disability Insurance Access Act was signed into law, which waives the mandatory five-month waiting period for ALS patients to receive Social …
December 2020 Foundation eNews
Be a Giver this Giving Tuesday This holiday season, your tax-deductible gift provides life-changing help to a person living with ALS. There is no better time to kick off your end of year giving than today, Giving Tuesday – the …
November 2020 Foundation eNews
Empowering through ALS Education We are excited to launch our new online learning series aimed at empowering our ALS community through the latest information and insights. Educational webinars and interactive Q&A’s covering a diverse array of topics, from telemedicine to …
October 2020 Foundation eNews
Join our 10th Annual Les Turner Symposium on ALS – Monday, November 9 Registration is now open for our 10th Annual Symposium, hosted by our own Les Turner ALS Center at Northwestern Medicine. This year’s event will be held virtually on …
September 2020 Foundation eNews
Join our 10th Annual Les Turner Symposium on ALS Registration is now open for our 10th Annual Symposium, hosted by our own Les Turner ALS Center at Northwestern Medicine. This year’s event will be held virtually on Nov, 9, and …
August 2020 Foundation eNews
New and Improved Clinical Trials Webpage While it may feel like much in life is on pause at the moment, there is exciting news in the ALS clinical trials and studies space, including information on the upcoming HEALEY ALS Platform …
July 2020 Foundation eNews
HEALEY ALS Platform Clinical Trial Update Our Les Turner ALS Center at Northwestern Medicine is a participating site for the first-ever ALS platform trial. The clinical drug trial, led by the Sean M. Healey & AMG Center at Massachusetts General …